Patients with immunoglobin A nephropathy who reached complete remission of proteinuria with sparsentan had greater eGFR ...

Ligand Pharmaceuticals (LGND) is a royalty investor in late-stage biopharma, with revenue and EPS growth driven by a robust ...

The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc.

Vertex is running a phase 2 trial of inaxaplin in APOL1-mediated kidney diseases, including some forms of FSGS. The phase 3 ...

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Investing.com -- HBM Healthcare Investments (SIX: HBMN) on Friday reported a quarterly profit of CHF 191 million in the third quarter, bringing nine-month earnings to CHF 286 million despite currency ...

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best mid-cap growth stocks to buy right now. On January 14, Bank of ...

The Food and Drug Administration has extended the review period for sparsentan in focal segmental glomerulosclerosis (FSGS).

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

CorMedix CRMD and Mirum Pharmaceuticals MIRM appeal to investors drawn to the rare-disease biotech space, where smaller ...

Nvidia and Eli Lilly unveiled a co-innovation AI Lab for drug discovery efforts. Nvidia announced a strategic collaboration ...